Royal Marsden NHS Foundation Trust
Royal Marsden NHS Foundation Trust
London, United Kingdom11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 1 | 2026-08-21 | NCT04360941 | |
| Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2026-07-28 | NCT06506955 | |
| Study of INBRX-109 in Conventional Chondrosarcoma | Conventional Chondrosarcoma | Active, not recruiting | Phase 2 | 2026-07-14 | NCT04950075 | |
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder | Active, not recruiting | Phase 3 | 2026-06-22 | NCT05059522 | |
| Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease | Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, Unilateral Breast Neoplasms, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-05-19 | NCT06760637 | |
| IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thyroid Cancer, Papillary, adenocarcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, papillary adenocarcinoma, thyroid Hurthle cell carcinoma, thyroid gland disorder, thyroid gland follicular carcinoma, thyroid tumor | Active, not recruiting | Phase 2 / Phase 3 | 2026-05-07 | NCT01398085 | |
| Breast Cancer Evolution During Neoadjuvant Systemic Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Not stated | 2026-04-16 | NCT06681064 | |
| Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-04-14 | NCT04920708 | |
| First in Human Study of T3P-Y058-739 (T3P) | neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-04-13 | NCT05120596 | |
| Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Not stated | 2026-03-12 | NCT07084571 | |
| Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck cancer, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Active, not recruiting | Phase 2 | 2025-08-01 | NCT04675294 |